{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 448230811
| IUPAC_name = (3''R'')-3-[di(cyclobutyl)amino]-8-fluoro-3,4-dihydro-2''H''-chromene-5-carboxamide
| image = Robalzotan.png

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Uncontrolled
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 72
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 169758-66-1
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 3055171
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = I18M56OGME
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 2316732

<!--Chemical data-->
| C=18 | H=23 | F=1 | N=2 | O=2 
| molecular_weight = 318.174 g/mol
| smiles = C1CC(C1)N(C2CCC2)[C@@H]3CC4=C(C=CC(=C4OC3)F)C(=O)N
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C18H23FN2O2/c19-16-8-7-14(18(20)22)15-9-13(10-23-17(15)16)21(11-3-1-4-11)12-5-2-6-12/h7-8,11-13H,1-6,9-10H2,(H2,20,22)/t13-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = MQTUXRKNJYPMCG-CYBMUJFWSA-N
}}

'''Robalzotan''' ('''NAD-299''', '''AZD-7371''') is a [[binding selectivity|selective]] [[receptor antagonist|antagonist]] at the [[5-HT1A|5-HT<sub>1A</sub>]] [[receptor (biochemistry)|receptor]].<ref name="pmid9851589">{{cite journal | doi = 10.1016/S0014-2999(98)00667-0 |vauthors=Jerning E, Svantesson GT, Mohell N | title = Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist. | journal = Eur J Pharmacol. | volume = 360 | issue = 2-3 | pages = 219–225 | year = 1998 | pmid = 9851589 }}</ref> It was shown to completely reverse the [[autoreceptor]]-mediated inhibition of [[serotonin]] release induced by the administration of [[selective serotonin reuptake inhibitors]] like [[citalopram]] in [[animal testing on rodents|rodent studies]].<ref name="pmid10528148">{{cite journal | doi = 10.1016/S0014-2999(99)00592-0 |vauthors=Arborelius L, Wallsten C, Ahlenius S, Svensson TH | title = The 5-HT(1A) receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing. | journal = Eur J Pharmacol. | volume = 382 | issue = 2 | pages = 133–138 | year = 1999 | pmid = 10528148 }}</ref> It was subsequently investigated by [[AstraZeneca]] as a potential [[antidepressant]] but like many other 5-HT<sub>1A</sub> ligands was discontinued.<ref name="pmid11249580">{{cite journal | author = Mucke HA. | title = Robalzotan AstraZeneca. | journal = Curr Opin Investig Drugs. | volume = 1 | issue = 2 | pages = 236–240 | year = 2000 | pmid = 11249580 }}</ref> Later on it was researched for other indications such as [[irritable bowel syndrome]] but was dropped once again.<ref name="pmid18775020">{{cite journal |vauthors=Drossman DA, Danilewitz M, Naesdal J, Hwang C, Adler J, Silberg DG | title = Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome | journal = The American Journal of Gastroenterology | volume = 103 | issue = 10 | pages = 2562–9 |date=October 2008 | pmid = 18775020 | doi = 10.1111/j.1572-0241.2008.02115.x}}</ref>

== See also ==
* [[Ebalzotan]]
* [[UH-301]]

== References ==
{{Reflist|2}}

{{Antidepressants}}
{{Anxiolytics}}
{{Drugs for functional gastrointestinal disorders}}
{{Serotonergics}}

[[Category:Amines]]
[[Category:Carboxamides]]
[[Category:Chromenes]]
[[Category:Fluoroarenes]]
[[Category:Cyclobutanes]]


{{gastrointestinal-drug-stub}}
{{nervous-system-drug-stub}}